Northwestern Medicine Selects Tempus to Expand Genomic Testing

Key Terms

genomic testing medical

A laboratory process that reads and analyzes a person’s DNA to identify genetic variations linked to disease risk, treatment response, or drug targets; think of it as reading a biological blueprint to predict problems and guide medical choices. Investors care because results drive demand for certain diagnostics, targeted therapies, and clinical trial designs, so advances, approvals, or reimbursement changes can directly affect revenue prospects and the value of healthcare companies.

next-generation sequencing medical

Next-generation sequencing is a set of laboratory techniques that read large amounts of DNA or RNA quickly and cheaply by processing millions of short genetic fragments in parallel, rather than one at a time. For investors, it matters because faster, lower-cost genetic data powers drug discovery, diagnostic tests and personalized medicine, creating scalable revenue opportunities and competitive advantages for companies that own the technology or services.

liquid biopsy medical

A liquid biopsy is a laboratory test that looks for tiny pieces of tumor or disease-related material — such as DNA, proteins, or cells — circulating in blood or other body fluids, allowing detection and monitoring without a surgical tissue sample. For investors, it matters because these tests can speed diagnosis, guide treatment choices, enable easier repeat testing, and create recurring revenue streams if adopted widely, affecting a medical company's growth and regulatory risk profile.

minimal residual disease (MRD) medical

The presence of minimal residual disease (MRD) means a very small number of cancer cells remain in the body after treatment, too few to cause symptoms or show up on routine scans but detectable with sensitive tests. For investors it matters because MRD status is a strong early indicator of whether a patient is likely to relapse and is increasingly used as a trial endpoint and regulatory signal, affecting a therapy’s market prospects and valuation much like finding glowing embers after a fire signals risk of re-ignition.

National Cancer Institute (NCI) medical

A U.S. government agency that leads and coordinates national cancer research, funds scientific studies, runs clinical trials, and sets research priorities. Think of it as a national referee and sponsor for cancer science: its funding decisions, trial results, and program endorsements can validate a therapy, lower development risk, steer research directions, and influence investor confidence and company valuations in the cancer‑focused biotech and pharmaceutical sectors.

National Comprehensive Cancer Network (NCCN) medical

A non-profit alliance of cancer centers that develops widely used clinical practice guidelines — think of it as a rulebook or recipe for diagnosing and treating different cancers. These guidelines influence which treatments doctors choose, whether insurers will cover them, and how new therapies are adopted, so they can meaningfully affect a drug or device’s market access, sales potential, and the design of clinical trials.

automatic shelf registration statement regulatory

An automatic shelf registration statement is a pre-approved filing that companies submit to securities regulators, allowing them to sell new shares or bonds quickly and efficiently when needed. It acts like a standing permit, enabling the company to raise money without going through a lengthy approval process each time, which can be helpful for responding promptly to market opportunities or needs. For investors, it provides transparency about the company's ability to raise funds and signals planning flexibility.

Rule 10b5-1 trading plan financial

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Collaboration will focus on the oncology patient population

CHICAGO--(BUSINESS WIRE)-- Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient across cancer types, including patients with early-stage cancer diagnoses, access to genomic testing. Patients will benefit from a deeper understanding of their unique cancer, enabling clinicians to deploy tailored, effective treatments.

“The collaboration with Tempus will substantially augment our existing precision oncology capabilities. Northwestern Medicine will now offer next-generation sequencing to patients with earlier-stage cancers,” said Dr Howard Chrisman, President and CEO of Northwestern Memorial HealthCare. “The data generated from this approach will allow us to rapidly adopt novel treatments and facilitate the design of innovative clinical trials aimed at developing personalized cancer treatments.”

Northwestern Medicine provides comprehensive cancer care, including state-of-the-art therapies and clinical trials. The health system is home to The Robert H. Lurie Comprehensive Cancer Center of Northwestern University, a National Cancer Institute (NCI)-designated Comprehensive Cancer Center and a founding member of the National Comprehensive Cancer Network (NCCN).

“This collaboration will deliver on our shared mission of driving the field of cancer testing forward by bringing the benefits of genomic testing to as broad a population as possible,” said Eric Lefkofsky, Founder and CEO of Tempus. “With one of the industry’s most comprehensive genomic portfolios and the operational infrastructure to support broad adoption, we look forward to supporting Northwestern Medicine in delivering more precise, personalized cancer care for their patients.”

As part of the collaboration, Tempus will offer NM access to its genomic testing including solid tissue, DNA and RNA profiling, liquid biopsy, minimal residual disease (MRD) and more.

About Northwestern Medicine

To learn more about Northwestern Medicine, please visit NM.org.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of Tempus’ portfolio of diagnostics and its capabilities for customers and the collaboration with Northwestern Medicine. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260112379072/en/

Erin Carron
media@tempus.com

Source: Tempus AI, Inc.